| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Vasicinone targets these cholinesterases, exhibiting promising anticholinesterase activity in preclinical models. Inhibition of AChE and BChE increases acetylcholine levels, which may be beneficial in neurodegenerative conditions such as Alzheimer's disease. The compound also has bronchodilatory and antioxidant activities.
|
|---|---|
| ln Vitro |
Vasicinone (1~30 µM; 24 hours; SH-SY5Y cells) can effectively counteract paraquat's detrimental effects on cell viability [1]. Vasicinone (10 and 15 μM; 24 hours; SH-SY5Y cells) can rescue paraquat-induced cells and attenuate the damage paraquat causes to SH-SY5Y cells by inhibiting the MAPK signaling pathway. It also dose-dependently lowers the percentage of apoptotic cells. Apoptosis [1] Apoptotic. Vasicinone (10 and 15 μM; SH-SY5Y cells) reduces the production of reactive oxygen species (ROS) and the expression of apoptotic proteins caused by paraquats [1].
In vitro, Vasicinone demonstrates anticholinesterase activity against AChE and BChE. At concentrations of 10 and 15 μM for 24 hours in SH-SY5Y cells, Vasicinone can rescue paraquat-induced cell damage and attenuate oxidative stress. The compound also exhibits antioxidant activity in nitric oxide and ABTS radical scavenging assays. (S)-Vasicinone exhibits antiproliferative activity against human gastric cancer cells MCG-803. |
| ln Vivo |
In vivo, Vasicinone has been shown to have hepatoprotective activity in mice. The compound exhibits significant antitussive, expectorant, and bronchodilating activities, which can be used to treat respiratory diseases. Its potential for Parkinson's disease and other neurodegenerative disorders is being investigated. Vasicinone's multiple pharmacological activities make it a compound of interest for various therapeutic applications.
|
| Enzyme Assay |
Cell-free enzyme assays for Vasicinone use purified acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) from electric eel or human sources. The compound is incubated with the enzyme and its substrate (acetylthiocholine or butyrylthiocholine) in the presence of Ellman's reagent (DTNB) at varying concentrations (0.01-1000 μM) for 15-30 minutes at room temperature. The production of the yellow chromophore is measured spectrophotometrically at 412 nm. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: SH-SY5Y Cell Tested Concentrations: 1~30 µM Incubation Duration: 24 hrs (hours) Experimental Results: Dramatically reversed the decrease in cell viability caused by paraquat. Western Blot Analysis [1] Cell Types: SH-SY5Y Cell Tested Concentrations: 10 and 15 µM Incubation Duration: 24 hrs (hours) Experimental Results: By inhibiting the MAPK signaling pathway, the damage caused by paraquat to SH-SY5Y cells is diminished. Apoptosis analysis[1] Cell Types: SH-SY5Y Cell Tested Concentrations: 10 and 15 µM Incubation Duration: 24 hrs (hours) Experimental Results: The percentage of apoptotic cells diminished in a dose-dependent manner. Cellular assays for Vasicinone are performed using neuroblastoma cell lines such as SH-SY5Y cells. Cells are seeded in 96-well plates and pre-treated with Vasicinone at concentrations ranging from 1-50 μM for 1-2 hours, then exposed to oxidative stress inducers such as paraquat or H2O2 for 24 hours. Cell viability is measured using MTT or CCK-8 assays. Oxidative stress markers such as reactive oxygen species (ROS), lipid peroxidation, and antioxidant enzyme levels are measured. Protection against oxidative stress-induced cell death is calculated from dose-response curves. |
| Animal Protocol |
In vivo efficacy studies are conducted in rodent models of respiratory disease (e.g., cough models, bronchoconstriction models) or neurodegenerative disease (e.g., MPTP-induced Parkinson's disease model). Vasicinone is administered orally or intraperitoneally at doses typically ranging from 1-50 mg/kg. In respiratory models, cough frequency, airway resistance, and bronchodilation are measured. In neurodegenerative models, behavioral tests (e.g., locomotor activity, rotarod) and biochemical markers (e.g., dopamine levels, oxidative stress markers) are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies of Vasicinone are limited. As a natural alkaloid, the compound is expected to have reasonable oral absorption and distribution. Its metabolic stability and half-life are determined in preclinical species. The compound's ability to cross the blood-brain barrier is of particular interest for its potential use in neurodegenerative diseases. Detailed PK parameters are not widely reported in public sources.
|
| Toxicity/Toxicokinetics |
Toxicological data for Vasicinone are limited. As a natural product, the compound has been used in traditional medicine, suggesting a reasonable safety profile at traditional doses. However, comprehensive toxicology studies would be required for clinical development. At research-grade doses, the compound is handled with standard laboratory precautions. No significant organ toxicity has been reported in published literature.
|
| References | |
| Additional Infomation |
Vasicinone belongs to the quinazoline class of compounds. It has been reported to exist in Arabidopsis tridentata, Gnaphalium affine, and other organisms with relevant data.
Vasicinone is a natural quinazoline alkaloid with multiple pharmacological activities, including anticholinesterase, bronchodilatory, hepatoprotective, and antioxidant effects. It is being investigated for potential use in respiratory diseases, Alzheimer's disease, and Parkinson's disease. The compound is available from chemical suppliers for research purposes. Its natural origin and diverse biological activities make it an interesting lead compound for drug development. The compound is typically stored at -20°C for long-term stability. |
| Molecular Formula |
C11H10N2O2
|
|---|---|
| Molecular Weight |
202.2093
|
| Exact Mass |
202.074
|
| Elemental Analysis |
C, 65.34; H, 4.98; N, 13.85; O, 15.82
|
| CAS # |
486-64-6
|
| PubChem CID |
442935
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
409.8±47.0 °C at 760 mmHg
|
| Melting Point |
200-202ºC
|
| Flash Point |
201.7±29.3 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.743
|
| LogP |
-0.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
327
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CN2C(=NC3=CC=CC=C3C2=O)[C@H]1O
|
| InChi Key |
SDIVYZXRQHWCKF-VIFPVBQESA-N
|
| InChi Code |
InChI=1S/C11H10N2O2/c14-9-5-6-13-10(9)12-8-4-2-1-3-7(8)11(13)15/h1-4,9,14H,5-6H2/t9-/m0/s1
|
| Chemical Name |
(3S)-3-hydroxy-2,3-dihydro-1H-pyrrolo[2,1-b]quinazolin-9-one
|
| Synonyms |
VASICINONE; 486-64-6; (-)-Vasicinone; l-Vasicinone; G6T5819NXM;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~247.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9454 mL | 24.7268 mL | 49.4535 mL | |
| 5 mM | 0.9891 mL | 4.9454 mL | 9.8907 mL | |
| 10 mM | 0.4945 mL | 2.4727 mL | 4.9454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
